Oddity Tech Ltd. (ODD)
| Market Cap | 1.07B -63.6% |
| Revenue (ttm) | 679.09M -9.7% |
| Net Income | 15.16M -86.2% |
| EPS | 0.27 -85.0% |
| Shares Out | 46.12M |
| PE Ratio | 86.03 |
| Forward PE | 22.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 900,744 |
| Open | 21.95 |
| Previous Close | 21.63 |
| Day's Range | 21.71 - 23.56 |
| 52-Week Range | 9.25 - 52.00 |
| Beta | 2.24 |
| Analysts | Hold |
| Price Target | 15.56 (-32.84%) |
| Est. Earnings | Nov 18, 2026 |
About ODD
Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States, Israel, and internationally. It serves consumers through its platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty, wellness, and technology products. The company provides a portfolio of products, including face and complexion, eye, brow and lip products, makeup tools, bodycare, medical grade presc... [Read more]
Financial Performance
In 2025, Oddity Tech's revenue was $809.84 million, an increase of 25.16% compared to the previous year's $647.04 million. Earnings were $110.75 million, an increase of 9.12%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ODD stock is "Hold." The 12-month stock price target is $15.56, which is a decrease of -32.84% from the latest price.
News
Oddity price target raised to $18.50 from $16.50 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Oddity (ODD) to $18.50 from $16.50 and keeps an Equal Weight rating on the shares.
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company's pr...
Oddity resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of Oddity (ODD) with a Neutral rating and $18 price target The firm is positive on Oddity’s “leading” scale, data-driven platform, and path toward a 2027 recovery.
Oddity price target raised to $18 from $16 at Truist
Truist raised the firm’s price target on Oddity (ODD) to $18 from $16 and keeps a Hold rating on the shares. Oddity’s Q2 results and Q3 outlook show sustained momentum…
Oddity price target raised to $10 from $8.50 at BofA
BofA raised the firm’s price target on Oddity (ODD) to $10 from $8.50 and keeps an Underperform rating on the shares. Q2 results were “better than feared” and show signs…
Oddity price target raised to $16.50 from $10 at Morgan Stanley
Morgan Stanley analyst Dara Mohsenian raised the firm’s price target on Oddity (ODD) to $16.50 from $10 and keeps an Equal Weight rating on the shares. Growth is recovering with…
Oddity price target raised to $9 from $8 at Goldman Sachs
Goldman Sachs analyst Bonnie Herzog raised the firm’s price target on Oddity (ODD) to $9 from $8 and keeps a Sell rating on the shares after its Q2 earnings beat.
Oddity price target raised to $18 from $16 at Jefferies
Jefferies raised the firm’s price target on Oddity (ODD) to $18 from $16 and keeps a Hold rating on the shares, calling the positive move in shares after the company…
Oddity Tech Earnings Call Transcript: Q2 2026
Net revenue declined 25% year-over-year due to IL MAKIAGE's ad algorithm issue, but SpoiledChild and METHODIQ showed strong growth and high repeat rates. The company expects sequential improvement, with Q3 revenue down ~5% and full-year revenue down ~19%.
Oddity Tech Earnings release: Q2 2026
Oddity Tech released its Q2 2026 earnings on September 9, 2026, summarizing the period's financial results.
Oddity Tech Prepared remarks: Q2 2026
Oddity Tech filed a regulatory document on September 9, 2026 disclosing important business information.
Oddity Tech Slides: Q2 2026
Oddity Tech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 9, 2026.
Oddity reports Q2 adjusted EPS 20c, consensus 12c
Reports Q2 revenue $180.52M, consensus $170.65M. “We made progress during the quarter, including strong results for both SpoiledChild and METHODIQ,” said Oran Holtzman, Oddity (ODD) co-founder and CEO...
ODDITY Tech Reports Second Quarter 2026 Results, Expects Sequential Revenue Improvement in the Third Quarter
Second quarter net revenue of $181 million, down approximately 25% year-over-year Second quarter adjusted EBITDA of $13 million Second quarter net income of $13 million and second quarter adjusted net...
Oddity price target raised to $16 from $12 at Truist
Truist raised the firm’s price target on Oddity (ODD) to $16 from $12 and keeps a Hold rating on the shares ahead of its Q2 results next week. The firm…
ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its second quarter 2026 financial results before the market open on Wednesday, September...
Oddity price target lowered to $15 from $23 at Evercore ISI
Evercore ISI lowered the firm’s price target on Oddity (ODD) to $15 from $23 and keeps an In Line rating on the shares. The firm is incrementally negative following a…
Oddity price target lowered to $8.50 from $10 at BofA
BofA lowered the firm’s price target on Oddity (ODD) to $8.50 from $10 and keeps an Underperform rating on the shares. The firm lowered its 2026 EPS estimate to 7c…
Oddity downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs downgraded Oddity (ODD) to Sell from Neutral with a price target of $8, down from $16.
Goldman downgrades Oddity to Sell on challenged path forward
Goldman Sachs downgraded Oddity (ODD) to Sell from Neutral with a price target of $8, down from $16, following the Q1 report. The stock in premarket trading is down 6%…
Oddity price target lowered to $10 from $16 at Morgan Stanley
Morgan Stanley analyst Dara Mohsenian lowered the firm’s price target on Oddity (ODD) to $10 from $16 and keeps an Equal Weight rating on the shares.
Oddity Tech Earnings Call Transcript: Q1 2026
Q1 2026 net revenue declined 26% year-over-year due to a technical issue with the largest ad partner, causing high CPA and reduced new customer acquisition. Remediation efforts are showing early signs of improvement, and full-year adjusted EBITDA is expected to be positive.
Oddity Tech Earnings release: Q1 2026
Oddity Tech released its Q1 2026 earnings on June 2, 2026, summarizing the period's financial results.
Oddity Tech Slides: Q1 2026
Oddity Tech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on June 2, 2026.